Short Reads

The ACM follows EU approach in its first pharmaceutical merger

The ACM follows EU approach in its first pharmaceutical merger

The ACM follows EU approach in its first pharmaceutical merger

07.02.2019 NL law

The Dutch Authority for Consumers and Markets (ACM) recently reviewed its first merger between two pharmaceutical companies. In its conditional clearance of Aurobindo's acquisition of certain European Apotex assets, the ACM followed the European Commission's approach in assessing the merger's impact on competition. Companies will welcome the news that pharma mergers will be reviewed in a similar fashion, irrespective of whether the ACM or the European Commission conducts the review.

The deal, worth EUR 74 million, involved India's Aurobindo acquiring Canadian Apotex's commercial operations and some of its supporting infrastructure in Poland, Czech Republic, Spain Belgium and the Netherlands. In the Dutch market, Aurobindo predominantly supplies prescription drugs to pharmacies, whereas Apotex's focus is on over-the-counter retail sales through drugstores and supermarkets (a substantial portion of which is private label sales). This diverging focus of the respective businesses was an important factor in the ACM's assessment.

Typically, pharmaceutical transactions are assessed by the European Commission in view of the turnover associated with pharmaceutical product portfolios. However, the Aurobindo/Apotex deal did not meet the European thresholds and therefore had to be reviewed by the Dutch and Polish competition authorities. The ACM followed the EU's industry-specific framework of analysing pharmaceutical mergers. In line with the Commission's approach, the ACM analysed overlaps at the level of the molecule limited to specific forms. The Dutch regulator also analysed the parties' pipeline, contract manufacturing and outlicensing activities. The only drug which raised concerns was the diazepam (enema), because the companies were the only suppliers of this drug in the Netherlands. The parties' commitment to divest Apotex's diazepam (enema) product remedied the ACM's competition concerns.

The ACM focuses on the pharmaceutical industry as part of its key priorities in 2019.

 

This article was published in the Competition Law Newsletter of February 2019. Other articles in this newsletter:

Team

Related news

22.07.2021 NL law
Towards a European legal framework for the development and use of Artificial Intelligence

Short Reads - Back in 2014, Stephen Hawking said, “The development of full artificial intelligence could spell the end of the human race.” Although the use of artificial intelligence is nothing new and dates back to Alan Turing (the godfather of computational theory), prominent researchers – along with Stephen Hawking – have expressed their concerns about the unregulated use of AI systems and their impact on society as we know it.

Read more

08.06.2021 NL law
Actualiteiten milieustrafrecht: zorgelijke ontwikkelingen

Short Reads - Vrijdag 28 mei jl. hadden wij een inspirerend webinar over actualiteiten op het gebied van milieustrafrecht. Wij spraken gedurende 90 minuten onder meer over aansprakelijkheden van bestuurders, de zorgplichten, incidentenrapportages vanuit strafrechtelijk- en bestuursrechtelijk perspectief.

Read more

03.06.2021 NL law
First material judgment in Dutch damages proceedings in trucks infringement

Short Reads - In its judgment of 12 May 2021, the Amsterdam District Court ruled that it has not been established that it is definitively excluded that the trucks infringement led to damage to the claimants. However, this does not alter the fact that it must still be assessed for each claimant whether the threshold for referral to the damages assessment procedure has been met. For this to be the case, it must be plausible that a claimant may have suffered damage as a result of the unlawful actions of the truck manufacturers. The Amsterdam District Court has not yet ruled on this issue.

Read more

08.06.2021 NL law
De Europese Klimaatwet uitgelicht

Short Reads - Op 21 april 2021 is een voorlopig akkoord bereikt over de Europese Klimaatwet. Deze Klimaatwet kan worden gezien als de kern van de Europese Green Deal, die in december 2019 werd gepubliceerd door de Europese Commissie. Het overstijgende doel van deze instrumenten is om een klimaatneutraal Europa te bewerkstelligen in 2050. De Europese Klimaatwet zorgt ervoor dat deze klimaatneutraliteitsdoelstelling in een Europese verordening wordt vastgelegd. Dit blogbericht gaat nader in op de Europese Klimaatwet en legt uit wat dit met zich brengt.

Read more